Calidi Biotherapeutics (CLDI)
:CLDI
Want to see CLDI full AI Analyst Report?
Top Page
Calidi Biotherapeutics
(CLDI)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.18
▲(0.56% Upside)
Action:Upgraded
Date:05/15/26
The score is held down primarily by weak financial performance (no revenue, sizable losses, and continued cash burn) and bearish technicals (price below major moving averages and negative MACD). Partially offsetting factors include balance-sheet repair (positive equity and reduced leverage) and some constructive platform progress, though dilution-related corporate actions remain a notable risk.
Positive Factors
Differentiated Platform Progress
Calidi’s RedTail platform shows mechanistic differentiation in preclinical data (CLD-401 immune recruitment; CLD-501 localized T-cell engager and IL-15 SA expression). These durable biological features can enhance systemic solid‑tumor activity and support long‑term clinical value if translated.
Negative Factors
No Commercial Revenue
Calidi remains a development‑stage biotech with zero commercial revenue, so long‑term sustainability depends entirely on clinical success or continued external funding. Lack of product cash flows increases binary outcome risk and limits the company’s ability to self‑fund R&D.
Read all positive and negative factors
Positive Factors
Negative Factors
Differentiated Platform Progress
Calidi’s RedTail platform shows mechanistic differentiation in preclinical data (CLD-401 immune recruitment; CLD-501 localized T-cell engager and IL-15 SA expression). These durable biological features can enhance systemic solid‑tumor activity and support long‑term clinical value if translated.
Read all positive factors
Calidi Biotherapeutics (CLDI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.39M
Dividend YieldN/A
Average Volume (3M)164.15K
Price to Earnings (P/E)―
Beta (1Y)0.74
Revenue GrowthN/A
EPS Growth76.55%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.19
Shares Outstanding19,311,625
10 Day Avg. Volume193,319
30 Day Avg. Volume164,153
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.34
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap-1.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.42
Enterprise Value/Ebitda0.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.52
Revenue Forecast (FY)N/A
Calidi Biotherapeutics Business Overview & Revenue Model
Company Description
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in m...
How the Company Makes Money
null...
Calidi Biotherapeutics Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
38
Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 45.00K | 449.00K |
| Gross Profit | -833.00K | -1.65M | 0.00 | -1.26M | -229.00K | 355.00K |
| EBITDA | -17.36M | -18.59M | -19.73M | -24.20M | -25.00M | -9.45M |
| Net Income | -19.03M | -19.91M | -22.14M | -29.22M | -25.43M | -10.93M |
Balance Sheet | ||||||
| Total Assets | 9.59M | 8.86M | 14.18M | 10.02M | 2.60M | 3.39M |
| Cash, Cash Equivalents and Short-Term Investments | 6.63M | 5.60M | 9.59M | 2.05M | 372.00K | 2.14M |
| Total Debt | 1.66M | 2.56M | 7.04M | 7.24M | 5.99M | 5.18M |
| Total Liabilities | 4.66M | 5.10M | 12.21M | 18.25M | 53.04M | 26.00M |
| Stockholders Equity | 4.93M | 3.76M | 1.53M | -8.23M | -50.44M | -22.61M |
Cash Flow | ||||||
| Free Cash Flow | -18.40M | -21.41M | -19.71M | -27.57M | -13.64M | -7.98M |
| Operating Cash Flow | -18.28M | -21.29M | -19.69M | -26.98M | -13.21M | -7.77M |
| Investing Cash Flow | -168.00K | -170.00K | -16.00K | -478.00K | -494.00K | -215.00K |
| Financing Cash Flow | 14.51M | 17.46M | 27.36M | 29.04M | 12.09M | 9.81M |
Calidi Biotherapeutics Technical Analysis
Negative
0.18
Price Trends
0.24
Negative
0.55
Negative
1.17
Negative
Market Momentum
-0.03
Negative
36.89
Neutral
51.37
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLDI, the sentiment is Negative. The current price of 0.18 is below the 20-day moving average (MA) of 0.20, below the 50-day MA of 0.24, and below the 200-day MA of 1.17, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 36.89 is Neutral, neither overbought nor oversold. The STOCH value of 51.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLDI.
Calidi Biotherapeutics Risk Analysis
Calidi Biotherapeutics disclosed 85 risk factors in its most recent earnings report. Calidi Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Calidi Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $4.46M | -0.30 | -155.01% | ― | ― | 75.60% | |
43 Neutral | $3.83M | -0.26 | -46.34% | ― | ― | 74.58% | |
42 Neutral | $3.39M | -0.15 | ― | ― | ― | 76.55% | |
42 Neutral | $1.17M | 0.19 | 1029.24% | ― | 155.96% | 87.56% |
* Healthcare Sector Average
CLDI
Calidi Biotherapeutics
0.18
-4.60
-96.30%
GLMD
Galmed Pharmaceuticals
0.63
-0.73
-53.68%
JAGX
Jaguar Animal Health
3.11
-155.09
-98.03%
ADIL
Adial Pharmaceuticals
2.24
-14.76
-86.82%
CDIO
Cardio Diagnostics Holdings
1.77
-2.54
-58.93%
Calidi Biotherapeutics Corporate Events
Business Operations and StrategyFinancial Disclosures
Calidi Highlights Q1 Results and RedTail Platform Progress
Positive
May 14, 2026
On May 14, 2026, Calidi Biotherapeutics reported first-quarter 2026 results and highlighted new preclinical data underscoring the potential of its RedTail-based candidates CLD-401 and CLD-501 to reshape immune activity in the tumor microenvironmen...
Private Placements and FinancingRegulatory Filings and Compliance
Calidi Biotherapeutics Issues Private Placement Warrant Financing
Neutral
May 8, 2026
On May 6, 2026, Calidi Biotherapeutics, Inc. issued a warrant to an accredited investor in a private placement, enabling the future purchase of up to 17,391,304 unvested shares of common stock at an exercise price of $0.23 per share. The warrant, ...
Business Operations and StrategyExecutive/Board Changes
Calidi Biotherapeutics Streamlines Board, Enhances Audit Oversight
Positive
Apr 2, 2026
On March 29, 2026, Calidi Biotherapeutics director Allan J. Camaisa notified the board’s Nominating and Corporate Governance Committee that he will allow his term to expire at the company’s 2026 annual stockholder meeting, with no disa...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Calidi Biotherapeutics Reports 2025 Results, Advances Oncology Pipeline
Negative
Mar 27, 2026
On March 27, 2026, Calidi Biotherapeutics reported fourth-quarter and full-year 2025 results, highlighting scientific and clinical progress alongside continued losses as it advances its oncology pipeline. The company formed a partnership with Avan...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Calidi Biotherapeutics Completes Dilutive Public Equity Offering
Negative
Mar 12, 2026
On March 6, 2026, Calidi Biotherapeutics, Inc. entered an underwriting agreement with Ladenburg Thalmann for an underwritten public offering of 2,278,731 common stock units and 9,815,900 pre-funded warrant units, raising about $6.03 million in gro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.